
    
      The purpose of this study is to determine whether BMN 190 is safe and effective in the
      treatment of patients with Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)
      disease. This is an open label Phase 1/2 study conducted in patients with CLN2 disease.
      Efficacy measures (disease rating scale and MRI) will be compared to a natural history
      control.

      The study will be conducted under cGCP and patients will be closely monitored.
    
  